The inhibitor of cyclin-dependent kinases 4 (CDK4), which has already been approved by the Food and Drug Administration (FDA) for the treatment of breast cancer (53, 54), markedly repressed the proliferation of Tregs (55). This evidence concerns the gene CDK4 and breast carcinoma.